New York, United States
miR Scientific, LLC is a healthcare company with a mission to revolutionize cancer management globally. The company has developed the proprietary miR Disease Management Platform®, focusing on early and accurate detection, characterization, and monitoring of diseases, particularly urological cancers. Their flagship product, the miR Sentinel® Prostate Cancer Test, is a non-invasive liquid biopsy urine test that can detect, classify, and monitor prostate cancer based on small-non-coding RNAs extracted from urinary exosomes.
Founded in 2013, miR Scientific is addressing the urgent need for improved standards of care in urologic oncology, including prostate, bladder, and urothelial cancers. The company's majority owner is Impact NRS LLC, with headquarters in New York City and operating subsidiaries in Israel, Canada, and Puerto Rico.
miR Scientific's innovative approach in the Biotechnology and Health Care industries positions it as a key player in transforming cancer management. With its focus on non-invasive and highly accurate diagnostic tools, miR Scientific presents an attractive opportunity for venture capital investment in the burgeoning field of precision medicine.
